Progress toward poliomyelitis eradication--Nigeria, 2005-2006

Only four countries (Afghanistan, India, Nigeria, and Pakistan) have never experienced interruption of poliovirus transmission. Nigeria had the largest number of cases in 2006, accounting for 1,129 (56%) of the 2,002 cases reported globally. However, major innovations to the national polio-eradication program in Nigeria were initiated in 2006. These innovations, if sustained, should advance the Global Polio Eradication Initiative. Nigeria (2006 population: 140 million) experienced a resurgence in wild poliovirus (WPV) transmission during 2003-2004 after a loss of public confidence in oral polio vaccine (OPV) and suspension of supplementary immunization activities (SIAs) in certain northern states. Subsequently, WPV spread within Nigeria and into 19 polio-free countries. Even after national SIAs recommenced, limited acceptance and ongoing operational problems resulted in low vaccination coverage and continued poliovirus transmission. The number of confirmed polio cases in Nigeria attributed to both WPV type 1 (WPV1) and type 3 (WPV3) increased from 782 in 2004 to 830 in 2005 and to 1,129 in 2006 (as of March 23, 2007). To increase the effectiveness of polio-eradication measures and community acceptance of vaccination, in 2006, health authorities in Nigeria introduced monovalent type 1 OPV (mOPV1) vaccine and changed the way SIAs were implemented. This report summarizes these new approaches and overall progress toward polio eradication in Nigeria during 2005-2006.

Failure to detect infection by oral polio vaccine virus following natural exposure among inactivated polio vaccine recipients

While oral polio vaccine (OPV) has been shown to be safe and effective, it has been observed that it can circulate within a susceptible population and revert to a virulent form. Inactivated polio vaccine (IPV) confers protection from paralytic disease, but provides limited protection against infection. It is possible, then, that an IPV-immunized population, when exposed to OPV, could sustain undetected circulation of vaccine-derived poliovirus. This study examines the possibility of polio vaccine virus circulating within the United States (highly IPV-immunized) population that borders Mexico (OPV-immunized). A total of 653 stool and 20 sewage samples collected on the US side of the border were tested for the presence of poliovirus. All samples were found to be negative. These results suggest that the risk of circulating vaccine-derived poliovirus is low in fully immunized IPV-using populations in developed countries that border OPV-using populations.

[Surveillance of acute flaccid paralysis in Belarus]

The ten-years experience of acute flaccid paralysis (AFP) surveillance in Belarus has been summarized. Among 456 AFP cases reported from 1996 to 2005, 11 were classified as vaccine-associated paralytic poliomyelitis (VAPP), 445--as non-polio AFP. The risk of VAPP for the period 1996-2001 was 1 case per 745,000 used doses of oral poliovaccine (OPV). For the recipients of OPV the risk was 1 case per 911,700 doses and for the first-dose recipients--1 case per 96,000 doses. The high incidence of VAPP was a reason for implementation of sequential polio vaccination schedule in 2000. Guillain-Barre syndrome dominated among non-polio AFP (39.3% of cases); more rare were traumatic neuritis (27.9% of cases), transient monoparalysis (12.1%), myelitis (7.6%). Non-polio AFP differed from VAPP by following epidemiological and virological characteristics: predominance of previously repeatedly vaccinated against poliomyelitis; development of paralysis in long-term period after vaccination; isolation of non-polio viruses belonged to three serotypes of Coxsackie B viruses (B1, B4, B6) and six serotypes of Echo viruses (6, 7, 11, 14, 24, 25) in 8.1% of cases; absence of typical for polio residual paralyses in patients who excreted vaccine polioviruses.

Use of mutational pattern in 5'-NCR and VP1 regions of polioviruses for molecular diagnosis

Polioviruses are members of the enterovirus genus, belonging to the Picornaviridae family. They are the causative agents of poliomyelitis, a paralytic and sometimes fatal disease in humans. The number of poliomyelitis cases caused by wild poliovirus infections has been dramatically reduced by the extensive use of two available vaccines: the inactivated poliovirus vaccine (IPV) and the oral poliovirus vaccine (OPV). Despite the importance of OPV in the reduction of poliomyelitis cases, one of the disadvantages associated with this vaccine is the rare occurrence of vaccine-associated paralytic poliomyelitis (VAPP) in vaccinees or their healthy contacts through the accumulation of mutations and/or recombination in Sabin strains genome. Thirteen clinical isolates originating from healthy vaccinees and VAPP cases were investigated in order to identify genomic modifications in 5' non-coding region (5'-NCR) and VP1 genomic regions. The analysis of samples was conducted by RT-PCR, RFLP, sequencing and bioinformatics analysis. All clinical isolates were characterized as OPV-like viruses. Our results showed that analysis of 5'-NCR and VP1 regions of Poliovirus Sabin strains is important in order to identify mutations that increase the neurovirulence conducting to the eventuality of emergence of VAPP cases.

The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative

Until 2008 poliomyelitis was controlled in Romania by predominantly using Oral Poliovirus Vaccine Sabin (OPV); the alternative vaccination schedule (IPV formalin Inactivated Poliovirus Vaccine/OPV) will be implemented starting September 2008. The vaccination coverage with 4 doses of TOPV (trivalent oral polio vaccine) in the first 14 months of life has been > 90% since 1980. In Romania, the risk of the Vaccine-Associated Paralytic Poliomyelitis cases (VAPP) decreased from less than 2 VAPP cases/year in the 1995-2006 interval to 0 VAPP cases in 2007. The serological study was performed in 2006-2007 only in cases with pair serum samples from 28 acute flaccid paralysis (AFP) cases (age = 3 months - 14 years) and from 45 facial paralysis (FP) cases (age -6 months - 4 years 9 months). A high level of vaccinal coverage was shown for all poliovirus serotypes: >95% in AFP serum samples investigated; and for FP serum samples investigated the levels of antibodies against poliovirus (PV) serotypes were 98% for PV type 1; 87% for PV type 2: and 89% for PV type 3. If the European region is polio free since 2002, the risk of wild PV importation from endemic region remains present. The laboratory capacity for the fast detection and molecular investigations of the emergence of the new epidemic strains and a high level of population immunity must be maintained. A national seroprevalence study concerning all three PV serotypes must be performed.

Clinical presentations of acute paralytic poliomyelitis

The concern about the emerging profile of poliovirus associated morbidity and mortality in the 21st century is legitimate [Paul Y. Clinical presentations of acute paralytic poliomyelitis. Vaccine 2005;23:5283]. Rather than case reports of several thousands, patients number at the most in few thousands. Furthermore, better diagnostic techniques have been offered to those handling patients with clinical syndromes resembling acute flaccid paralysis. Bizarre and unconventional clinical presentations might well be a rule than exception in near future. Furthermore, MRI can be used in the diagnosis of anterior horn infection and would play an important role in diagnosis of poliomyelitis [Kornreich L, Dagan O, Grunebaum M. MRI in acute poliomyelitis. Neuroradiology 1996;38(4):371-2]. Imaging techniques would be important in diagnosis of acute flaccid paralysis.

Vaccine-associated paralytic poliomyelitis caused by contact infection

We encountered an adult patient with acute anterior poliomyelitis (AAP), whose monoparesis developed 28 days after his son's immunization with oral poliovirus vaccine (OPV). Neurological and electrophysiological examinations suggested that his muscular wasting of the left lower limb was due to a lower motor neuron disorder, and magnetic resonance imaging revealed the responsible lesion in the left anterior horn at the thoracolumbar junction. His stool was found to include poliovirus type 3, mainly originating from Sabin 3 by neutrization antibody and PCR-restriction fragment length polymorphism method. This indicated that the AAP resulted from contact with his son. This patient raises the question about OPV in polio-free countries.

[Serous meningitis]

During the second half of the 1950s serous meningitis and other enterovirus-induced diseases played one of the leading roles in human pathology in the world. Since the introduction of oral poliomyelitis vaccine (OPV) into wide medical practice from the beginning of the 1960s and during the subsequent decades the number of epidemics and the morbidity level in enterovirus-induced diseases sharply dropped. This was probably due to the interference of enteroviruses circulating in nature and vaccine polioviruses in the intestine of vaccinated children. At the beginning of the XXI century a tendency towards a growth in the morbidity of serous meningitis of enterovirus etiology was noted. This growth was probably due to a sharp decrease in the level of revaccinations of children with OPV. At the age of 2 to 14 years, most affected by enteroviruses, children were not vaccinated with OPV and they were thus left unprotected. The materials on the epidemiology of serous meningitis and recommendations on etiological diagnosis, as well as on the patients hospitalization and the vaccination of children with OPV as a nonspecific antiepidemic measures based on the phenomenon of virus interference are presented.

Motor unit number estimates correlate with strength in polio survivors

Motor unit number estimation (MUNE) has been proposed as an outcome measure in clinical trials for the motor neuron diseases. One major criticism of MUNE is that it may not represent a clinically meaningful endpoint. We prospectively studied a cohort of polio survivors over a period of 15 years with respect to MUNE and strength. We identified a significant association between thenar MUNE and arm strength, extensor digitorum brevis MUNE and leg strength, and the summated MUNE and global strength of the polio survivors. These findings confirm the clinical relevance of MUNE as an outcome measure in the motor neuron diseases and provide further validation for its use in clinical trial research.

Reflexes in prior polio and their relation to weakness and anterior horn cell loss

The aim of this study was to evaluate the reflex pattern in patients with prior polio and to relate these findings to the degree of anterior horn cell (AHC) involvement and loss of muscle force. Twenty-five prior polio subjects were investigated with electromyography (EMG), force testing and reflex studies, which included the patellar and Achilles reflex, H-reflex, T-response and interlimb reflex (ILR). The clinical reflexes, H/M-ratio and T-response amplitude at rest were positively correlated with force and negatively correlated with the degree of AHC loss. The H/M-ratio was decreased compared with age matched controls. ILR was present in 68% of the prior polio patients but did not exist in controls. The presence of the ILR was not correlated with the degree of AHC loss or force. The reflex studies gave two main findings. The first is reduced excitability of monosynaptic connections in the motor neuron pool, which is related to weakness. The other is the presence of ILR as an indicator of interneuronal hyper-excitability, which is not related to weakness.

Detecting polio through surveillance for acute flaccid paralysis (AFP)

Accurate surveillance for polio is essential for eradication. Surveillance systems for polio has been developed under the guidance of the global polio eradication initiative. Surveillance of cases of acute flaccid paralysis among children less than 15 years of age is a key component for a well functioning polio surveillance system. The surveillance system works through a network of surveillance medical officers, the responsibility of them lies in assisting the health services departments of all states and maintaining a network of acute flaccid paralysis reporting sites and rapidly investigating the cases. Surveillance activities begin when a child comes in contact with a healthcare provider who in turn informs the officer in charge of acute flaccid paralysis surveillance. The goal of the polio network laboratories is to provide accurate and timely results of wild poliovirus detection in stool samples of cases of acute flaccid paralysis. Strong linkages have been established between the acute flaccid paralysis surveillance system and the laboratory network. Laboratories complete poliovirus isolation and if poliovirus is isolated, these are submitted for intratypic differentiations. Acute flaccid paralysis surveillance in India has demonstrated that the eradication activities implemented in India led to dramatic reduction and restriction in the number of cases and geographic spread of poliovirus transmission.

Laboratory surveillance for wild and vaccine-derived polioviruses, January 2004-June 2005

A global network of 145 virology laboratories has been established by the World Health Organization (WHO) to support surveillance activities of the Polio Eradication Initiative (PEI). The Global Polio Laboratory Network analyzes stool specimens from patients with acute flaccid paralysis (AFP) and environmental samples for the presence of polioviruses. Surveillance systems detect at least one AFP case per 100,000 persons aged <15 years, collect adequate stool samples from patients, and send the samples to network laboratories for analysis. Laboratory data are used to identify locations where wild polioviruses (WPVs) or vaccine-derived polioviruses (VDPVs) are circulating, target supplementary immunization activities (SIAs) to interrupt transmission chains, and investigate genetic relationships among viral isolates. This report updates previous publications and describes the laboratory network's performance during the period January 2004-June 2005.

Immune status to poliovirus among immigrant workers in Israel

BACKGROUND

An essential part of the progress towards the global eradication of poliomyelitis is the ongoing evaluation of populations immunity. Migration of unregistered individuals poses a challenge to such estimations. Moreover, partially immunized immigrants might enlarge immunity gaps and facilitate polio outbreaks in their destination countries.

OBJECTIVES

To study the level of immunity to polio in adult foreign workers in Israel.

METHODS

Foreign workers (n = 145) from the Philippines, India, and Western Africa were tested for neutralizing antibodies against three IPV strains and an outbreak-associated wild virus. Demographic and immunization data were collected by questionnaires.

RESULTS

Seropositivity rates and geometric mean titers (GMTs) for the Mahoney (type 1), MEF (type 2), and Saukett (type 3) poliovirus strains and the wild poliovirus type 1 strain were 99.3% (GMT--233.8), 98.6% (GMT--268.5), 99.3% (GMT--89.4), and 99.3% (GMT--139.5), respectively. Higher GMTs were associated with parenthood and older age. African individuals had significantly higher GMTs for the Saukett strain, compared with individuals from the Philippines and India.

CONCLUSIONS

Our results indicate a high level of immunity among foreign workers. More serosurveys are indicated in the future in order to monitor the level of immunity in residents in Israel.